Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Inclusion Criteria: * Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study: * Is a man or woman and is \> 55 of age, whereby females must be without childbearing potential (confirmed by either: age \>/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start) * Has at least 6 years of education * Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures * Possesses a general health that permits adequate compliance with all study procedures * The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study * Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients) * Inclusion criteria for HV only: * Has no evidence of cognitive impairment * Has MRI brain scan that has been judged as "normal" (age- appropriate) * Inclusion criteria for patients with AD only: * Presents with positive assessment for dementia of Alzheimer's type * Does not fulfill the criteria Dementia with Lewy Bodies (DLB) or Vascular Dementia (VaD) * MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease * Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver Exclusion Criteria: * Has any contraindication to MRI examination scan * Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application * Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma) * is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable * Has a history of exposure to any radiation \>15 milli Sieverts (mSv)/year (e.g. occupational or radiation therapy) * Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy) * Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical * Has a brain tumor or other intracranial lesion, a disturbance of cerebro-spinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery * Has an inflammatory or infectious central nervous system (CNS) disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease * Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness * Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function) * Has a history of alcohol or drug abuse * Has history of severe persistent depression